Grifols, S.A. (NASDAQ:GRFS) Shares Purchased by US Bancorp DE

US Bancorp DE boosted its position in shares of Grifols, S.A. (NASDAQ:GRFS) by 12.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,663 shares of the biotechnology company’s stock after buying an additional 2,256 shares during the period. US Bancorp DE’s holdings in Grifols were worth $183,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in GRFS. GAMMA Investing LLC grew its position in shares of Grifols by 49.4% during the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 1,135 shares during the last quarter. Signaturefd LLC grew its position in Grifols by 66.2% during the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 2,153 shares during the last quarter. AQR Capital Management LLC acquired a new position in Grifols in the second quarter valued at $89,000. Cetera Advisors LLC purchased a new stake in shares of Grifols in the first quarter valued at about $147,000. Finally, Creative Planning boosted its stake in shares of Grifols by 26.4% during the third quarter. Creative Planning now owns 17,319 shares of the biotechnology company’s stock worth $154,000 after buying an additional 3,614 shares during the period.

Analyst Ratings Changes

Separately, Berenberg Bank upgraded Grifols to a “strong-buy” rating in a research report on Tuesday, October 29th.

Grifols Stock Performance

Grifols stock opened at $9.55 on Friday. The business has a 50 day simple moving average of $8.85 and a 200-day simple moving average of $7.97. Grifols, S.A. has a 12 month low of $5.30 and a 12 month high of $12.15. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.